Which weight‑loss medications are covered by Connecticut Medicaid?

Connecticut Medicaid Coverage for Weight Loss Medications

Connecticut Medicaid has extremely limited coverage for weight loss medications, with most states' Medicaid programs—including Connecticut—covering few to no FDA-approved anti-obesity medications as of recent data.

Current Coverage Landscape

Based on the most recent evidence, only 16 state Medicaid programs indicated coverage for pharmacotherapy for obesity as of 2017, with no net increase from 2009 1. A 2018 analysis confirmed that only seven state Medicaid programs have drug coverage for obesity medications 2. Connecticut is not consistently listed among states with robust anti-obesity medication coverage in Medicaid.

Medications Most Likely to Have Coverage

If Connecticut Medicaid does provide any coverage for weight loss medications, the following are your best options in order of likelihood:

1. Orlistat (Xenical/Alli)

• Most likely to be covered due to its long-standing FDA approval, lower cost, and established safety profile
• Mechanism: Lipase inhibitor blocking ~30% of fat absorption
• Expected weight loss: 3.1% at 1 year 3
• Safest option for patients with cardiovascular disease 3
• Side effects: Gastrointestinal (oily spotting, fecal urgency, fatty stools)

2. Phentermine (Adipex)

• Generic medication, lower cost
• Short-term FDA approval only (not for long-term use)
• Expected weight loss: 5.1% at 28 weeks 3
• Contraindicated in cardiovascular disease 3
• Schedule IV controlled substance

3. Metformin (off-label)

• While not FDA-approved for obesity, may be covered for patients with:
  • Type 2 diabetes
  • Prediabetes
  • Polycystic ovary syndrome (PCOS)
• Promotes modest weight loss 3

Medications Unlikely to Be Covered

The following newer, more effective medications are rarely covered by Medicaid programs 2:

• Semaglutide 2.4 mg (Wegovy) - Most effective (10.76% weight loss) 4 but expensive
• Liraglutide 3.0 mg (Saxenda) - 4.81% weight loss 4
• Phentermine/Topiramate ER (Qsymia) - 8.45% weight loss 4
• Naltrexone/Bupropion ER (Contrave) - 3.01% weight loss 4

Critical Prescribing Criteria

For any medication to be considered (if covered), patients must meet:

• BMI ≥30 kg/m² OR
• BMI ≥27 kg/m² with weight-related comorbidities (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea) 3

Medications must be combined with intensive lifestyle intervention—never used alone 3.

Efficacy Monitoring

Discontinue medication if:

• <5% weight loss at 12 weeks for most medications 3
• <3% weight loss at 12 weeks for phentermine/topiramate ER at recommended dose 5

Practical Recommendations

Step 1: Verify Current Coverage

Call Connecticut Medicaid pharmacy services directly to confirm current formulary status, as coverage policies change and published data may be outdated.

Step 2: Prior Authorization Strategy

If medications require prior authorization, document:

• BMI with weight-related comorbidities
• Failed lifestyle intervention attempts (diet, exercise, behavioral therapy)
• Medical necessity for expedited weight loss

Step 3: Alternative Approaches

If anti-obesity medications are not covered:

• Prioritize intensive lifestyle intervention (diet, exercise, behavioral therapy) 3
• Consider bariatric surgery referral for BMI ≥40 or BMI ≥35 with comorbidities (Medicaid coverage for bariatric surgery increased to 49 states by 2017) 1
• Use diabetes medications with weight loss benefits if patient has type 2 diabetes (GLP-1 agonists like liraglutide 1.8 mg for diabetes may be covered) 3

Common Pitfalls

• Medicare explicitly excludes weight loss drugs from Part D coverage 2, 6, but this does NOT apply to Medicaid
• Do not assume newer GLP-1 agonists are covered—they rarely are in Medicaid despite superior efficacy
• Avoid sympathomimetic agents (phentermine, phentermine/topiramate) in patients with cardiovascular disease 3

The reality is that Connecticut Medicaid likely covers very few, if any, FDA-approved anti-obesity medications, making orlistat your most realistic option if any coverage exists at all 1, 2.